<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898556</url>
  </required_header>
  <id_info>
    <org_study_id>IP-ROSA2020</org_study_id>
    <secondary_id>2020-004517-12</secondary_id>
    <nct_id>NCT04898556</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy of Prasterone Treatment for Atrophy Vulvovaginal in Postmenopausal Women With Vulvar / Vestibular Pain</brief_title>
  <acronym>ROSA</acronym>
  <official_title>Clinical Study to Evaluate the Efficacy of Prasterone Treatment for Atrophy Vulvovaginal in Postmenopausal Women With Vulvar / Vestibular Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Santiago Palacios</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Palacios</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open, randomized and controlled clinical intervention study in women over 45&#xD;
      years of age with a diagnosis of vulvovaginal atrophy (dryness and / or dyspareunia, etc.)&#xD;
      and vulvar and / or vestibular pain. The efficacy of Prasterone treatment is evaluated in&#xD;
      those patients willing to undergo the treatment compared to the control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A sample of 50 women over 45 years of age with at least one year of amenorrhea and who&#xD;
      require treatment for vulvovaginal atrophy of moderate and / or severe intensity and who&#xD;
      present vulvar and vaginal pain within these symptoms will be chosen.&#xD;
&#xD;
      At the beginning of the study, after passing the selection criteria and signing the informed&#xD;
      consent, the patients will be randomly assigned to one of the two arms of the study, (active&#xD;
      group) or (control group), said assignment will be made randomly. Through a computer program&#xD;
      where one or the other arm of treatment will be assigned to the patient at random to&#xD;
      guarantee the homogeneity of both study groups and thus avoid selection biases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interventional, prospective, open, randomized and controlled clinical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment for vulvar / vestibular pain for patients with vulvovaginal atrophy</measure>
    <time_frame>Screening Visit 1 (Day 0)</time_frame>
    <description>Clinical study to evaluate the efficacy of Prasterone treatment for vulvovaginal atrophy in postmenopausal women with vulvar / vestibular pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment for vulvar / vestibular pain for patients with vulvovaginal atrophy</measure>
    <time_frame>Visit 2 (Week 4)</time_frame>
    <description>Clinical study to evaluate the efficacy of Prasterone treatment for vulvovaginal atrophy in postmenopausal women with vulvar / vestibular pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment for vulvar / vestibular pain for patients with vulvovaginal atrophy</measure>
    <time_frame>Visit 3 (Week 12)</time_frame>
    <description>Clinical study to evaluate the efficacy of Prasterone treatment for vulvovaginal atrophy in postmenopausal women with vulvar / vestibular pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of vulvo vestibular pain</measure>
    <time_frame>Screening Visit 1 (Day 0); Visit 2 (Week 4); Visit 3 (Week 12)</time_frame>
    <description>Through the visual analog scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of vulvovaginal vascularization</measure>
    <time_frame>Screening visit 1 (Day 0); Visit 3 (Week 12)</time_frame>
    <description>Through the ECO DOPPLER</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Ph and cytological maturity index</measure>
    <time_frame>Screening Visit 1 (Day 0); Visit 3 (Week 12)</time_frame>
    <description>On the lateral side of the vagina we take the Ph sample through a strip, and the cytological maturity is taken through a swab to take a sample from the cervical area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the clinical index of vulvar and vaginal health</measure>
    <time_frame>Screening Visit 1 (Day 0); Visit 3 (Week 12)</time_frame>
    <description>It is carried out through a clinical parameter that takes into account humidity, hydration, elasticity, pH among others ...</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vulvovaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will undergo treatment with Intrarosa (Prasterone 6.5mg) in ovules, will apply one ovule a day before going to bed for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who will not undergo any treatment for vulvovaginal atrophy for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasterone 6.5 MG</intervention_name>
    <description>The dose to be applied will be one Intrarosa ovule (Prasterone 6.5mg) a day before going to bed for 12 weeks.</description>
    <arm_group_label>Active Treatment</arm_group_label>
    <other_name>Active Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients with a diagnosis of VVA who will not undergo treatment for 12 weeks.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Control Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women over 45 years of age with at least one year of amenorrhea and at least one&#xD;
             symptom of vulvovaginal atrophy of moderate and / or severe intensity.&#xD;
&#xD;
          -  Women with moderate to severe vulvar / vestibular pain&#xD;
&#xD;
          -  Women without symptoms or signs of acute vaginal infection.&#xD;
&#xD;
          -  Women without symptoms of urinary infection and a negative urine strip result.&#xD;
&#xD;
          -  Woman willing to carry out the study procedures and comply with the visits.&#xD;
&#xD;
          -  Woman who signs the Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hormone treatment in the last three months for vulvovaginal atrophy&#xD;
&#xD;
          -  Treatment with vaginal moisturizers in the last week for vulvovaginal atrophy&#xD;
&#xD;
          -  Laser treatment in the last 6 months.&#xD;
&#xD;
          -  Acute and recurrent urinary tract infections in the last 3 months.&#xD;
&#xD;
          -  Acute genital infections (herpes, candida, etc)&#xD;
&#xD;
          -  Personal history of cancer at any level&#xD;
&#xD;
          -  Present alterations in the area to be treated, such as lacerations, abrasions or&#xD;
             ulcers (resolution time at the medical discretion)&#xD;
&#xD;
          -  Decompensated non-communicable chronic diseases (Diabetes Mellitus, Heart Disease ...)&#xD;
&#xD;
          -  Participation in a clinical study 3 months before inclusion or during this study.&#xD;
&#xD;
          -  Hypersensitivity to the active principle or any of the excipients&#xD;
&#xD;
          -  Undiagnosed vaginal bleeding.&#xD;
&#xD;
          -  Untreated endometrial hyperplasia&#xD;
&#xD;
          -  Acute liver disease or a history of liver disease while liver function tests remain&#xD;
             impaired.&#xD;
&#xD;
          -  Current diagnosis or history of venous thromboembolism (deep vein thrombosis,&#xD;
             pulmonary embolism)&#xD;
&#xD;
          -  Known thrombophilic disorders (protein C, protein S, or antithrombin deficiency)&#xD;
&#xD;
          -  Current or recent diagnosis of arterial thromboembolic disease (angina, myocardial&#xD;
             infarction)&#xD;
&#xD;
          -  Porphyria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Santiago Palacios Palacios, PI</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>ipalacios@institutopalacios.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dra. Marieta Ramirez, SI</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>investigacion@institutopalacios.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Palacios</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Palacios, PI</last_name>
      <phone>+34 91 578 05 17</phone>
      <email>investigacion@institutopalacios.com</email>
    </contact>
    <contact_backup>
      <last_name>Marieta Ramirez, SI</last_name>
      <phone>+34 91 578 05 17</phone>
      <email>investigacion@institutopalacios.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Santiago Palacios, PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dra. Marieta Ramirez, SI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Palacios</investigator_affiliation>
    <investigator_full_name>Dr. Santiago Palacios</investigator_full_name>
    <investigator_title>Investigador Principal</investigator_title>
  </responsible_party>
  <keyword>Vultar/vestibular pain</keyword>
  <keyword>Dyspareunia</keyword>
  <keyword>Vaginal dryness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

